NO20045023L - Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer - Google Patents

Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Info

Publication number
NO20045023L
NO20045023L NO20045023A NO20045023A NO20045023L NO 20045023 L NO20045023 L NO 20045023L NO 20045023 A NO20045023 A NO 20045023A NO 20045023 A NO20045023 A NO 20045023A NO 20045023 L NO20045023 L NO 20045023L
Authority
NO
Norway
Prior art keywords
crystals
steroids
pharmaceutical formulations
preparation
particle size
Prior art date
Application number
NO20045023A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hosel
Uwe Mueller
Annette Eichardt
Hagen Gerecke
Sabine Gliesing
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20045023L publication Critical patent/NO20045023L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0085—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det er beskrevet en fremgangsmåte for fremstilling av krystaller av steroider hvis gjennomsnittlige partikkelstørrelse Ugger i et på forhånd gitt orm-åde og hvis maksimale partikkelstørrelse ikke overskrider en på forhånd gitt verdi, hvorved en overmettet oppløsning av steroidene under krystalhsasjonen underkastes en våtmaling ved hjelp av en irmretning for våtmaling, hvorved en primærkomsuspensjon oppnås. Det er videre beskrevet ved derme fremgangsmåten oppnåelige krystaller samt farmasøytiske formuleringer irmeholdende disse.
NO20045023A 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer NO20045023L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10218107A DE10218107A1 (de) 2002-04-23 2002-04-23 Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
PCT/EP2003/004154 WO2003091272A1 (de) 2002-04-23 2003-04-22 Verfahren zum herstellen von kristallen von steroiden, danach erhältliche kristalle und deren verwendung in pharmazeutischen formulierungen

Publications (1)

Publication Number Publication Date
NO20045023L true NO20045023L (no) 2004-11-18

Family

ID=29264787

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045023A NO20045023L (no) 2002-04-23 2004-11-18 Fremgangsmate for fremstilling av krystaller av steroider, de derved oppnaelige krystallene og deres anvendelse i farmasoytiske formuleringer

Country Status (20)

Country Link
US (1) US7148212B2 (no)
EP (1) EP1497308B1 (no)
JP (1) JP4490116B2 (no)
KR (1) KR20040106380A (no)
CN (1) CN1646555A (no)
AT (1) ATE340186T1 (no)
AU (1) AU2003232491A1 (no)
BR (1) BR0309357A (no)
CA (1) CA2480004C (no)
DE (2) DE10218107A1 (no)
DK (1) DK1497308T3 (no)
ES (1) ES2274258T3 (no)
IL (1) IL163986A0 (no)
MX (1) MXPA04010467A (no)
NO (1) NO20045023L (no)
PL (1) PL371340A1 (no)
PT (1) PT1497308E (no)
RU (1) RU2315056C2 (no)
WO (1) WO2003091272A1 (no)
ZA (1) ZA200409401B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
SI1886694T1 (sl) * 2006-08-10 2009-10-31 Bayer Schering Pharma Ag Peroralna medikamentna oblika z dienogestom in etinilestradiolom za kontracepcijo
US20080038350A1 (en) * 2006-08-10 2008-02-14 Hagen Gerecke Low-dosage peroral medication for contraception containing crystalline dienogest and ethinyl estradiol
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
RU2642244C2 (ru) * 2010-04-12 2018-01-24 Кларус Терапеутикс, Инк. Оральные фармацевтические композиции сложных эфиров тестостерона и способы лечения недостатка тестостерона с их использованием
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
CA2947459A1 (en) 2014-05-13 2015-11-19 Akzo Nobel Chemicals International B.V. Process to crystallize chelating agents
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
EP4151219A4 (en) 2020-05-15 2024-05-15 Shionogi & Co., Ltd DRUG COMPOSITION WITH INHIBITED IMPURITIES PRODUCTION

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3226389A (en) * 1962-01-04 1965-12-28 Du Pont 11,11,12,12-tetracyano-naphtho-2,6-quinodimethan and its anion-radical salts
AU624421B2 (en) 1988-10-05 1992-06-11 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE3917617A1 (de) * 1989-05-31 1990-12-06 Boehringer Ingelheim Kg Mikronisierte bioabbaubare partikel, verfahren zur ihrer herstellung und ihre verwendung
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
DE69227850T2 (de) 1991-07-10 1999-04-29 Chiyoda Corp., Yokohama Verfahren zur Herstellung eines Kristallinadduktes von Bisphenol A mit Phenol
NZ248813A (en) * 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR0151363B1 (ko) * 1993-12-27 1998-10-01 시모무라 스스무 4-히드록시-4'-이소프로폭시디페닐 술폰 현상조성물, 습식분쇄방법, 및 분산액
US5718388A (en) * 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
CN1183102C (zh) * 1998-12-25 2005-01-05 第一精密化学株式会社 泛酸钙的制备方法
EP1157996A1 (de) * 2000-05-23 2001-11-28 JENAPHARM GmbH Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen

Also Published As

Publication number Publication date
RU2315056C2 (ru) 2008-01-20
US7148212B2 (en) 2006-12-12
DE50305122D1 (de) 2006-11-02
JP2005524698A (ja) 2005-08-18
ATE340186T1 (de) 2006-10-15
CN1646555A (zh) 2005-07-27
ZA200409401B (en) 2006-02-22
EP1497308A1 (de) 2005-01-19
ES2274258T3 (es) 2007-05-16
RU2004134324A (ru) 2006-02-10
EP1497308B1 (de) 2006-09-20
JP4490116B2 (ja) 2010-06-23
PL371340A1 (en) 2005-06-13
KR20040106380A (ko) 2004-12-17
CA2480004A1 (en) 2003-11-06
DK1497308T3 (da) 2007-01-29
AU2003232491A1 (en) 2003-11-10
DE10218107A1 (de) 2003-11-20
MXPA04010467A (es) 2004-12-13
PT1497308E (pt) 2007-01-31
BR0309357A (pt) 2005-02-22
WO2003091272A1 (de) 2003-11-06
IL163986A0 (en) 2005-12-18
US20030216360A1 (en) 2003-11-20
CA2480004C (en) 2007-11-13

Similar Documents

Publication Publication Date Title
NO20045073L (no) Fremgangsmate for fremstilling av krystaller, derved oppnaelige krystaller og deres anvendelse i farmasoytiske formuleringer
WO2003002196A3 (en) Multi-site ventricular pacing system measuring qrs duration
ATE246702T1 (de) Verfahren zur darstellung von oligonukleotiden
NO994671L (no) Aryl- eller heteroarylsulfonamid-substituerte hydroksamsyrederivater, fremgangsmåte til fremstilling derav og deres anvendelse som farmasöytika
DK214480A (da) Fremgangsmaade til fremstilling af 2-(pyrimidinylamino)-1,3-diaza-2-cycloalkenforbindelser deres tautomere forbindelser og syreadditionssalte deraf
NZ579082A (en) Stable suspensions of micronised particles of a solid organic compound which is free of surfactants, thickeners, poly-electrolytes or block copolymers
DK1497308T3 (da) Fremgangsmåde til fremstilling af krystaller af steroider, krystaller opnået ved hjælp heraf og anvendelse heraf i farmaceutiske formuleringer
CA2072233A1 (en) Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them
EP0073340A3 (en) Titanium dioxide pigment having improved photostability and process for producing same
CA2482021A1 (en) Removal of adenine during a process of pathogen reducing blood and blood components
ATE496868T1 (de) Verfahren zur herstellung von siliciumdioxid aus olivin
HRP20020167B1 (en) Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms
NO20045071L (no) Fremgangsmate for fremstilling av krystaller ut i fra aktive legemiddelvirkestoffer, krystaller oppnadd derav og deres anvendelse i farmasoytiske formuleringer
Nielsen et al. Studies of hydrogen-bonded 5'-guanosine monophosphate self-associates using low-frequency Raman scattering
Kapoor et al. Orotidine-5′-phosphate pyrophosphorylase of wheat embryos
CA2316739A1 (en) Preparation of cells for production of biologicals
SU1366475A1 (ru) Способ обесфторивани азотнофосфорнокислого раствора
YU107779A (en) Process for preparing derivatives of benzoylphenoxyalkanoic acid, which normalize the blood lipide level
JPH07114570B2 (ja) コーティング種子及びその製造方法
CN103755758A (zh) 一种制霉菌素的制备方法
ATE178051T1 (de) Verfahren zur herstellung einer physikalisch stabilen, kristallinen gamma-modifikation von para-aminobenzolsulfonamid
DuCHESNE Hybridization in the Methyl Radical of CH3X Molecules
IE791438L (en) Oxadiazolotriazines
JPS54118656A (en) Treatment method of waste water containing starch
JPS537519A (en) Concentrating method for titanium component

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application